TNFRSF12A mRNA Expression and distribution of TNFRSF12A+ cells in rat liver during thioacetamide-induced fibrogenesis
- Authors: Lebedeva E.I.1, Shchastniy A.T.1, Babenka A.S.2
-
Affiliations:
- Vitebsk State Order of Peoples’ Friendship Medical University
- Belarussian State Medical University
- Issue: No 1 (2024)
- Pages: 14-24
- Section: БИОЛОГИЯ КЛЕТКИ
- URL: https://journals.rcsi.science/1026-3470/article/view/255487
- DOI: https://doi.org/10.31857/S1026347024010023
- EDN: https://elibrary.ru/LWFVIA
- ID: 255487
Cite item
Full Text
Abstract
TNFRSF12A mRNA expression and distribution of TNFRSF12A+ cells were studied in detail for the first time at different stages of fibrosis in rat liver. Under physiological conditions, the expression level of TNFRSF12A mRNA was 0.224 (95% CI: 0.170–0.277). At the same time, cells expressing the TNFRSF12A marker were practically absent. In bridging fibrosis, the first peak of TNFRSF12A mRNA growth (p = 0.000) and an increase in the area of TNFRSF12A+ cells (p = 0.000) was established. The second peak (p = 0.000) was detected during the process of transformation of fibrosis into cirrhosis. At the stage of incomplete cirrhosis, a sharp drop was noted. A subsequent increase in the expression of TNFRSF12A mRNA and the area of TNFRSF12A+ cells was observed from the stage of significant cirrhosis. Immunohistochemical method revealed two groups of TNFRSF12A+ cells. In the sinusoidal capillaries TNFRSF12A+, the cells had a shape close to flat and resembled endotheliocytes, while in the fibrous connective tissue they were rounded. The number of α-SMA+ cells increased gradually (p = 0.000) before the onset of significant cirrhosis, and then there was a sharp increase (p = 0.000).
Keywords
Full Text
About the authors
Elena I. Lebedeva
Vitebsk State Order of Peoples’ Friendship Medical University
Author for correspondence.
Email: lebedeva.ya-elenale2013@yandex.ru
Belarus, Frunze Ave., 27, Vitebsk, 210009
Anatoly T. Shchastniy
Vitebsk State Order of Peoples’ Friendship Medical University
Email: lebedeva.ya-elenale2013@yandex.ru
Belarus, Frunze Ave., 27, Vitebsk, 210009
Andrei S. Babenka
Belarussian State Medical University
Email: lebedeva.ya-elenale2013@yandex.ru
Belarus, Dzerzhinsky ave., 83, building 15, Minsk, 220116
References
- Банин В.В., Быков В.Л. Международные термины по цитологии и гистологии человека с официальным списком русских эквивалентов. М.: ГЭОТАР-Медиа, 2009. 272 с.
- Коржевский Д.Э. Теоретические основы и практическое применение методов иммуногистохимии. СПб.: СпецЛит, 2014. 119 с.
- Жижин К.С. Медицинская статистика: учебное пособие. Ростов н/Д: Феникс, 2007. 160 с.
- Breit H.C., Block K.T., Winkel D.J., Gehweiler J.E., Henkel M.J., Weikert T., Stieltjes B., Boll D.T., Heye T.J. Evaluation of liver fibrosis and cirrhosis on the basis of quantitative T1 mapping: Are acute inflammation, age and liver volume confounding factors? // Eur. J. Radiol. 2021. № 141. Р. 109789. https://doi.org/10.1016/j.ejrad.2021.109789
- Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease // Cytokine. 2007. V. 40. № 1. Р. 1–16. https://doi.org/10.1016/j.cyto.2007.09.007
- Cai J., Hu M., Chen Z., Ling Z.J. The roles and mechanisms of hypoxia in liver fibrosis // Transl. Med. 2021. V. 19. № 1. Р. 186. https://doi.org/10.1186/s12967-021-02854-x
- Chen H.N., Wang D.J., Ren M.Y., Wang Q.L., Sui S.J. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кB pathway // Mol. Biol. Rep. 2012. V. 39. № 8. Р. 8231–41. https://doi.org/10.1007/s11033-012-1671-3
- Chen W., Liu Y., Chen J., Ma Y., Song Y., Cen Y., You M., Yang G. The Notch signaling pathway regulates macrophage polarization in liver diseases // Int. Immunopharmacol. 2021. № 99. Р. 107938. https://doi.org/10.1016/j.intimp.2021.107938
- Cheng D., Chai J., Wang H., Fu L., Peng S., Ni X. Hepatic macrophages: Key players in the development and progression of liver fibrosis // Liver Int. 2021. V. 41. № 10. Р. 2279–2294. https://doi.org/10.1111/liv.14940
- Dwyer B.J., Jarman E.J., Gogoi-Tiwari J., Ferreira-Gonzalez S., Boulter L., Guest R.V., Kendall T.J., Kurian D., Kilpatrick A.M., Robson A.J., O’Duibhir E., Man T.Y., Campana L., Starkey Lewis P.J., Wigmore S.J., Olynyk J.K., Ramm G.A., Tirnitz-Parker J.E.E., Forbes S.J. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression // J. Hepatol. 2021. V. 74. № 4. Р. 860–872. https://doi.org/10.1016/j.jhep.2020.11.018
- Esmail M.M., Saeed N.M., Michel H.E., El-Naga R.N. The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways // Toxicol. Lett. 2021. № 347. Р. 23–35. https://doi.org/10.1016/j.toxlet.2021.04.018
- Everhart J.E., Wright E.C., Goodman Z.D., Dienstag J.L., Hoefs J.C., Kleiner D.E., Ghany M.G., Mills A.S., Nash S.R., Govindarajan S., Rogers T.E., Greenson J.K., Brunt E.M., Bonkovsky H.L., Morishima C., Litman H.J., Group H. ALT-C. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial // Hepatology. 2010. V. 51. № 2. Р. 585–94. https://doi.org/10.1002/hep.23315
- Gomez I.G., Roach A.M., Nakagawa N., Amatucci A., Johnson B.G., Dunn K., Kelly M.C., Karaca G., Zheng T.S., Szak S., Peppiatt-Wildman C.M., Burkly L.C., Duffield J.S. TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease // J Am Soc. Nephrol. 2016. V. 27. № 12. Р. 3639–3652. https://doi.org/10.1681/ASN.2015111227
- Guerrier M., Attili F., Alpini G., Glaser S. Prolonged administration of secretin to normal rats increases biliary proliferation and secretin-induced ductal secretory activity // Hepatobiliary Surg. Nutr. 2014. V. 3. № 3. Р. 118–25. https://doi.org/10.3978/j.issn.2304-3881.2014.04.04
- Jakubowski A., Ambrose C., Parr M., Lincecum J.M., Wang M.Z., Zheng T.S., Browning B., Michaelson J.S., Baetscher M., Wang B., Bissell D.M., Burkly L.C. TWEAK induces liver progenitor cell proliferation // J. Clin. Invest. 2005. V. 115. № 9. Р. 2330–40. https://doi.org/10.1172/JCI23486
- Khan S., Saxena R. Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review // Adv. Anat. Pathol. 2021. V. 28. № 6. Р. 408–414. https://doi.org/10.1097/PAP.0000000000000312
- Kisseleva T., Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression // Nat. Rev. Gastroenterol. Hepatol. 2021. V. 18. № 3. Р. 151–166. https://doi.org/10.1038/s41575-020-00372-7
- Li N., Hu W.J., Shi J., Xue J., Guo W.X., Zhang Y., Guan D.X., Liu S.P., Cheng Y.Q., Wu M.C., Xie D., Liu S.R., Cheng S.Q. Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma // Asian Pac. J. Cancer. Prev. 2013. V. 14. № 6. Р. 3509–14. https://doi.org/10.7314/apjcp.2013.14.6.3509
- Li S., Gan L., Tian Y.J., Tian Y., Fan R.Z., Huang D., Yuan F.Y., Zhang X., Lin Y., Zhu Q.F., Tang G.H., Yan X.L., Yin S. Presegetane diterpenoids from Euphorbia sieboldiana as a new type of anti-liver fibrosis agents that inhibit TGF-β/Smad signaling pathway // Bioorg. Chem. 2021. № 114. Р. 105222. https://doi.org/10.1016/j.bioorg.2021.105222
- Liu Q.W., Ying Y.M., Zhou J.X., Zhang W.J., Liu Z.X., Jia B.B., Gu H.C., Zhao C.Y., Guan X.H., Deng K.Y., Xin H.B. Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice // Stem. Cell Res. Ther. 2022. V. 13. № 1. Р. 224. https://doi.org/10.1186/s13287-022-02906-z
- Odagiri N., Matsubara T., Sato-Matsubara M., Fujii H., Enomoto M., Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future // Clin. Mol. Hepatol. 2021. V. 27. № 3. Р. 413–424. https://doi.org/10.3350/cmh.2020.0187
- Rockey D.C., Friedman S.L. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside // Gastroenterology. 2021. V. 160. № 5. Р. 1502–1520.e1. https://doi.org/10.1053/j.gastro.2020.09.065
- Tadokoro T., Morishita A., Masaki T. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA // Int. J. Mol. Sci. 2021. V. 22. № 15. Р. 8139. https://doi.org/10.3390/ijms22158139
- Voutilainen S.H., Kosola S.K., Lohi J., Mutka A., Jahnukainen T., Pakarinen M., Jalanko H. Expression of 6 Biomarkers in Liver Grafts After Pediatric Liver Transplantation: Correlations with Histology, Biochemistry, and Outcome // Ann Transplant. 2020. № 25. Р. e925980. https://doi.org/10.12659/AOT.925980
- Wang M., Xie Z., Xu J., Feng Z. TWEAK/Fn14 axis in respiratory diseases // Clin. Chim. Acta. 2020. № 509. Р. 139–148. https://doi.org/10.1016/j.cca.2020.06.007
- Weiskirchen R. Special Issue on “Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis” // Cells. 2020. V. 9. № 5. Р. 1105. https://doi.org/10.3390/cells9051105
- Wilhelm A., Shepherd E.L., Amatucci A., Munir M., Reynolds G., Humphreys E., Resheq Y., Adams D.H., Hübscher S., Burkly L.C., Weston C.J., Afford S.C. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation // J. Pathol. 2016. V. 239. № 1. Р. 109–21. https://doi.org/10.1002/path.4707
- Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting // Nat. Rev. Drug. Discov. 2008. V. 7. № 5. Р. 411–25. https://doi.org/10.1038/nrd2488
- Zhang Y., Zeng W., Xia Y. TWEAK/Fn14 axis is an important player in fibrosis // J. Cell Physiol. 2021. V. 236. № 5. Р. 3304–3316. https://doi.org/10.1002/jcp.30089
- Zheng L., Lv Z., Gong Z., Sheng Q., Gao Z., Zhang Y., Yu S., Zhou J., Xi Z., Wang X. Fn14 hepatic progenitor cells are associated with liver fibrosis in biliary atresia // Pediatr. Surg. Int. 2017. V. 33. № 5. Р. 593–599. https://doi.org/10.1007/s00383-017-4068-5